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tion unknown, and the published trials do not allow
any conclusion about its efficacy (let alone its effective›
ness or cost effectiveness). In its defence it does seem to
be very safe—and any safe, effective compound used for
osteoarthritis could do much good, even if the effect
size is small. However, given the confusion we cannot
recommend its wholesale use. We need large clinical
trials, without company interference.
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Twenty years of AIDS, and no end in sight
A BMJ theme issue will refocus attention on this catastrophic epidemic
AMartian researcher is sent to earth. His missionis to assess a pandemic sweeping the southernhemisphere. On returning to Mars he files his
report: “Human beings are undergoing one of the
greatest catastrophes in recorded history. The epi›
demic rages far beyond their control and is steadily
gaining momentum. Widespread misery, the devasta›
tion of communities, and death outpace the inconse›
quential expenditures of governments in denial.
Nothing stands in its way.”
All this began without fanfare. In 1981 the Morbid›
ity and Mortality Weekly Report published a small case
series of five gay men in Los Angeles who had Pneumo›
cystis carinii—a rare form of pneumonia usually found
in people with immune dysfunction.1 Since then, the
disease has left 23 million dead; it will have killed 55
million by 2010. Africa suffers most of the disease bur›
den. India is next in line.
Why did the Martian’s report fail to mention the
United Nations Secretary General’s call for a $10bn
(£7bn) global health and AIDS fund?2 Because the
international response has been feeble. President Bush
has pledged only $200m, when a donation of $2.5bn
would have been consistent with his country’s wealth.3
Worse, as the southern pandemic spirals out of control,
northern development assistance has fallen to its low›
est level in 20 years.4
Drug company discounting of various medications
is largely immaterial since the most heavily indebted
countries still cannot afford them. And heterosexual
transmission rates, and thus incidence, will probably
remain high in many southern regions with or without
medications.
The HIV tragedy in the south must be foremost on
every country’s agenda. The BMJ wants to help by pub›
lishing a theme issue in January 2002 on “Global
voices on the HIV catastrophe.” By focusing on the
south, we aim to boost international and cross›cultural
understanding and cooperation. We want to stimulate
inquiry, attract high quality research, and collect
outstanding educational materials to improve clinical
practice among all people infected or affected by HIV.
Among other topics, the issue will include the long
term care of AIDS orphans, influencing the social sta›
tus of women, reducing mother›to›child transmission,
the opportunities and pitfalls of an HIV vaccine, and
prospects for an effective response by the global health
community. We welcome your manuscripts for any sec›
tion of the journal, but particularly research papers on
the HIV epidemic in the developing world. The closing
date for submissions is 1 August 2001; please email
them to papers@bmj.com.
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